Information Provided By:
Fly News Breaks for October 7, 2019
TMDX
Oct 7, 2019 | 07:58 EDT
Cowen analyst Joshua Jennings said the recent weakness in TransMedics is a buying opportunity as there has been no deterioration in the fundamentals that would justify the move. The analyst said his confidence in the 2019 numbers remains unchanged and he sees several catalysts upcoming that could facilitate a rebound in sentiment. Jennings reiterated his Outperform rating and $40 price target on TransMedics shares.
News For TMDX From the Last 2 Days
TMDX
Mar 28, 2024 | 05:16 EDT
Piper Sandler analyst Matt O'Brien initiated coverage of TransMedics with an Overweight rating and $95 price target. The analyst believes the company is changing the organ transplant market with proprietary organ preservation technologies and wholly-owned transport services. TransMedics' patented devices better preserve organs while its logistical network beats the outdated models, the analyst tells investors in a research note. The firm believes the company is building a "sizable moat around its business" with these transport services, which will "elevate its value in the coming years."
TMDX
Mar 27, 2024 | 16:26 EDT
Meeting to be held in Andover, MA on April 2 hosted by Oppenheimer.